SBIR/STTR Research Award

Discovering novel natural products from fungal species

Award identifier a6d4e8588a995228a110fd8df9fdb60279269ee1f0353dd1744bba8b26767e40Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$308,925

Program and phase

SBIR · Phase I

Award year

2024

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CHEMIA BIOSCIENCES, INC.
Proposal award date
2024-09-01
Contract end date
2025-08-31
UEI
F91YML3Q7YU3
Solicitation number
PA23-230
Topic code
300

Research abstract

Project Summary. Antibiotic resistance is becoming a major public health problem worldwide, with antibiotic resistant pathogens infecting hundreds of millions and killing over a million patients worldwide each year. Infections such as pneumonia, tuberculosis, blood poisoning, gonorrhoea, and foodborne diseases are becoming harder or impossible to treat with the existing medicine. Majority of antibiotics currently in clinical use are natural products or their derivatives. However, recently discovery of natural products with novel mechanisms to kill pathogens have become more challenging due to the high rate of rediscovery of known molecules, as the traditional technologies only capture the highest abundant molecular products of microbial isolates. The introduction of modern sequencing technologies and genome mining in early 2000 has revolutionized the field of natural product discovery. While these technologies have revealed millions of biosynthetic gene clusters (BGCs, clusters of genes that encode for natural products) in microbial genomes, currently these methods cannot predict the precise action of enzymes in BGCs, and therefore fail to correctly predict the final molecular product of BGCs. Chemia Biosciences is developing technologies to predict the molecular product of these BGCs based on high- throughput mass spectrometry data collected on extracts of microbial cultures. In the past, the PI and co-PI have developed techniques for identifying known and discovering novel bacterial natural products by a computational analysis of mass spectrometry data. The main goal of this proposal is to develop methods for discovering novel fungal natural products, a biomedically important class of natural products that include antibacterial penicillin, antifungal echinocandin, anticancer paclitaxel, immunosuppressant cyclosporin, and cholesterol-lowering medication lovastatin. The software developed in the course of this proposal will be available to partners as a cloud service.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

5 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $1,939,440. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Energy

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.